{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T06:24:20Z","timestamp":1772000660835,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.acuroe.2025.501758","type":"journal-article","created":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T11:14:02Z","timestamp":1745061242000},"page":"501758","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["New insights and emerging approaches in bladder-sparing treatment for muscle-invasive bladder cancer"],"prefix":"10.1016","volume":"49","author":[{"given":"J.D.","family":"Subiela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Guerrero-Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d3.","family":"Rodr\u00edguez-Faba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Aumatell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Gajate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"L\u00f3pez-Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Sevillano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hern\u00e1ndez-Arroyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Garc\u00eda-Rojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Artiles Medina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"S\u00e1enz-Calzada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"G\u00f3mez-Ca\u00f1izo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Romero-Otero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felipe","family":"Cou\u00f1ago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.acuroe.2025.501758_bib0005","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines","volume":"85","author":"Alfred Witjes","year":"2024","journal-title":"Eur Urol."},{"issue":"4","key":"10.1016\/j.acuroe.2025.501758_bib0010","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-043266","article-title":"Short-term morbidity and mortality following radical cystectomy: a systematic review","volume":"11","author":"Maibom","year":"2021","journal-title":"BMJ Open."},{"issue":"6","key":"10.1016\/j.acuroe.2025.501758_bib0015","doi-asserted-by":"crossref","first-page":"272.e1","DOI":"10.1016\/j.urolonc.2021.12.015","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive urothelial carcinoma of the bladder","volume":"40","author":"Softness","year":"2022","journal-title":"Urol Oncol."},{"issue":"6","key":"10.1016\/j.acuroe.2025.501758_bib0020","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol."},{"issue":"6_suppl","key":"10.1016\/j.acuroe.2025.501758_bib0025","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1200\/JCO.2018.36.6_suppl.490","article-title":"Clinical outcomes of patients with histologic variants of urothelial carcinoma treated with tetra-modality bladder-sparing protocol incorporating consolidative partial cystectomy","volume":"36","author":"Kijima","year":"2018","journal-title":"Journal of Clinical Oncology."},{"issue":"1","key":"10.1016\/j.acuroe.2025.501758_bib0030","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.eururo.2016.12.002","article-title":"Clinical outcomes of patients with histologic variants of urothelial cancer treated with trimodality bladder-sparing therapy","volume":"72","author":"Krasnow","year":"2017","journal-title":"Eur Urol."},{"issue":"9","key":"10.1016\/j.acuroe.2025.501758_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0222223","article-title":"Prognostic value of preoperative hydronephrosis in patients with bladder cancer undergoing radical cystectomy: a meta-analysis","volume":"14","author":"Zhu","year":"2019","journal-title":"PLoS One."},{"issue":"4","key":"10.1016\/j.acuroe.2025.501758_bib0040","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol."},{"issue":"2","key":"10.1016\/j.acuroe.2025.501758_bib0045","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eururo.2019.04.036","article-title":"Molecular subtyping of clinically localized urothelial carcinoma reveals lower rates of pathological upstaging at radical cystectomy among luminal tumors","volume":"76","author":"Lotan","year":"2019","journal-title":"Eur Urol."},{"issue":"1","key":"10.1016\/j.acuroe.2025.501758_bib0050","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.eururo.2019.01.011","article-title":"Impact of immune and stromal infiltration on outcomes following bladder-sparing trimodality therapy for muscle-invasive bladder cancer","volume":"76","author":"Efstathiou","year":"2019","journal-title":"Eur Urol."},{"issue":"13","key":"10.1016\/j.acuroe.2025.501758_bib0055","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22137204","article-title":"The abscopal effect in the era of checkpoint inhibitors","volume":"22","author":"Kodet","year":"2021","journal-title":"Int J Mol Sci."},{"issue":"7693","key":"10.1016\/j.acuroe.2025.501758_bib0060","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature."},{"issue":"1","key":"10.1016\/j.acuroe.2025.501758_bib0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-06654-8","article-title":"TGF-beta-associated extracellular matrix genes link cancer-associated fibroblasts to immune evasion and immunotherapy failure","volume":"9","author":"Chakravarthy","year":"2018","journal-title":"Nat Commun."},{"issue":"5","key":"10.1016\/j.acuroe.2025.501758_bib0070","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.eururo.2019.12.016","article-title":"Multiparametric magnetic resonance imaging as a noninvasive assessment of tumor response to neoadjuvant pembrolizumab in muscle-invasive bladder cancer: preliminary findings from the PURE-01 study","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol."},{"issue":"5","key":"10.1016\/j.acuroe.2025.501758_bib0075","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.euo.2020.06.004","article-title":"The value of multiparametric magnetic resonance imaging sequences to assist in the decision making of muscle-invasive bladder cancer","volume":"4","author":"Bandini","year":"2021","journal-title":"Eur Urol Oncol."},{"key":"10.1016\/j.acuroe.2025.501758_bib0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejrad.2022.110587","article-title":"Quantitative multiparametric MRI as a promising tool for the assessment of early response to neoadjuvant chemotherapy in bladder cancer","volume":"157","author":"Yang","year":"2022","journal-title":"Eur J Radiol."},{"issue":"3","key":"10.1016\/j.acuroe.2025.501758_bib0085","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.euf.2021.05.005","article-title":"Role of radiomics in the prediction of muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"8","author":"Kozikowski","year":"2022","journal-title":"Eur Urol Focus."},{"issue":"2","key":"10.1016\/j.acuroe.2025.501758_bib0090","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.crad.2022.08.149","article-title":"Introduction to radiomics for a clinical audience","volume":"78","author":"McCague","year":"2023","journal-title":"Clin Radiol."},{"issue":"1","key":"10.1016\/j.acuroe.2025.501758_bib0095","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00330-021-08110-6","article-title":"Usefulness of texture features of apparent diffusion coefficient maps in predicting chemoradiotherapy response in muscle-invasive bladder cancer","volume":"32","author":"Kimura","year":"2022","journal-title":"Eur Radiol."},{"key":"10.1016\/j.acuroe.2025.501758_bib0100","article-title":"Development of a MRI-based radiomics nomogram for prediction of response of patients with muscle-invasive bladder cancer to neoadjuvant chemotherapy","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol."},{"issue":"6","key":"10.1016\/j.acuroe.2025.501758_bib0105","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","article-title":"Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer","volume":"68","author":"Plimack","year":"2015","journal-title":"Eur Urol."},{"issue":"16_suppl","key":"10.1016\/j.acuroe.2025.501758_bib0110","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4615","article-title":"A phase II study of gemcitabine plus cisplatin chemotherapy in patients with muscle-invasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response (DDR) gene alterations (Alliance A031701)","volume":"40","author":"Iyer","year":"2022","journal-title":"Journal of Clinical Oncology."},{"issue":"6_suppl","key":"10.1016\/j.acuroe.2025.501758_bib0115","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1200\/JCO.2023.41.6_suppl.438","article-title":"A phase II trial of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN)","volume":"41","author":"Geynisman","year":"2023","journal-title":"Journal of Clinical Oncology."},{"issue":"6_suppl","key":"10.1016\/j.acuroe.2025.501758_bib0120","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1200\/JCO.2023.41.6_suppl.447","article-title":"Co-primary endpoint analysis of HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC)","volume":"41","author":"Galsky","year":"2023","journal-title":"Journal of Clinical Oncology."},{"issue":"1","key":"10.1016\/j.acuroe.2025.501758_bib0125","first-page":"12","article-title":"Abscopal regression of antigen disparate tumors by antigen cascade after systemic tumor vaccination in combination with local tumor radiation","volume":"27","author":"Hodge","year":"2012","journal-title":"Cancer Biother Radiopharm."},{"issue":"4","key":"10.1016\/j.acuroe.2025.501758_bib0130","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s13566-019-00411-0","article-title":"Intensity-modulated radiotherapy is superior to three-dimensional conformal radiotherapy in the trimodality management of muscle-invasive bladder cancer with daily cone beam computed tomography optimization","volume":"8","author":"Sherry","year":"2019","journal-title":"J Radiat Oncol."},{"issue":"9","key":"10.1016\/j.acuroe.2025.501758_bib0135","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.clon.2019.06.005","article-title":"Adaptive radiotherapy for carcinoma of the urinary bladder: long-term outcomes with dose escalation","volume":"31","author":"Murthy","year":"2019","journal-title":"Clin Oncol (R Coll Radiol)."},{"issue":"1","key":"10.1016\/j.acuroe.2025.501758_bib0140","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.critrevonc.2014.11.007","article-title":"A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC)","volume":"94","author":"Arcangeli","year":"2015","journal-title":"Crit Rev Oncol Hematol."},{"key":"10.1016\/j.acuroe.2025.501758_bib0145","first-page":"46","article-title":"Feasibility of magnetic resonance guided radiotherapy for the treatment of bladder cancer","volume":"25","author":"Hunt","year":"2020","journal-title":"Clin Transl Radiat Oncol."},{"issue":"1","key":"10.1016\/j.acuroe.2025.501758_bib0150","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.radonc.2011.01.027","article-title":"\u2019Plan of the day\u2019 adaptive radiotherapy for bladder cancer using helical tomotherapy","volume":"99","author":"Murthy","year":"2011","journal-title":"Radiother Oncol."},{"issue":"6","key":"10.1016\/j.acuroe.2025.501758_bib0155","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/j.clon.2021.02.012","article-title":"Advancing radiotherapy for bladder cancer: randomised phase II trial of adaptive image-guided standard or dose-escalated tumour boost radiotherapy (RAIDER)","volume":"33","author":"Hafeez","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)."},{"issue":"2","key":"10.1016\/j.acuroe.2025.501758_bib0160","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1470-2045(20)30607-0","article-title":"Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials","volume":"22","author":"Choudhury","year":"2021","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.acuroe.2025.501758_bib0165","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ijrobp.2020.11.068","article-title":"Clinical outcomes of a randomized trial of adaptive plan-of-the-day treatment in patients receiving ultra-hypofractionated weekly radiation therapy for bladder cancer","volume":"110","author":"Huddart","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"5","key":"10.1016\/j.acuroe.2025.501758_bib0170","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.ijrobp.2018.04.070","article-title":"Dose-limiting urinary toxicity with pembrolizumab combined with weekly hypofractionated radiation therapy in bladder cancer","volume":"101","author":"Tree","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"6","key":"10.1016\/j.acuroe.2025.501758_bib0175","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1464-410X.2011.10425.x","article-title":"Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: oncological outcomes of the initial 46 patients","volume":"109","author":"Koga","year":"2012","journal-title":"BJU Int."},{"issue":"2","key":"10.1016\/j.acuroe.2025.501758_bib0180","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bju.14736","article-title":"Selective tetramodal bladder-preservation therapy, incorporating induction chemoradiotherapy and consolidative partial cystectomy with pelvic lymph node dissection for muscle-invasive bladder cancer: oncological and functional outcomes of 107 patients","volume":"124","author":"Kijima","year":"2019","journal-title":"BJU Int."},{"issue":"1","key":"10.1016\/j.acuroe.2025.501758_bib0185","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1080\/02656736.2022.2109763","article-title":"Tetramodal therapy with transurethral resection followed by chemoradiation in combination with hyperthermia for muscle-invasive bladder cancer: early results of a multicenter phase IIB study","volume":"39","author":"Riesterer","year":"2022","journal-title":"Int J Hyperthermia."},{"issue":"6_suppl","key":"10.1016\/j.acuroe.2025.501758_bib0190","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS584","article-title":"SunRISe-4: TAR-200 plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or refuse neoadjuvant platinum-based chemotherapy","volume":"41","author":"Psutka","year":"2023","journal-title":"J Clin Oncol."}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578625000897?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173578625000897?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T08:46:32Z","timestamp":1757839592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173578625000897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":38,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S2173578625000897"],"URL":"https:\/\/doi.org\/10.1016\/j.acuroe.2025.501758","relation":{},"ISSN":["2173-5786"],"issn-type":[{"value":"2173-5786","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New insights and emerging approaches in bladder-sparing treatment for muscle-invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuroe.2025.501758","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2025.501758","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"501758"}}